

August 10, 2022

Mark J. Rosenblum  
Chief Financial Officer  
Salarius Pharmaceuticals, Inc.  
2450 Holcombe Blvd., Suite X  
Houston, TX 77021

Pharmaceuticals, Inc.  
Statement on Form S-3  
2022

Re: Salarius  
Registration  
Filed August 5,  
File No. 333-266589

Dear Mr. Rosenblum:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Alan Campbell at 202-551-4224 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc:  
Esq.

Stephen M. Nicolai,